Researchers have completed enrollment for a Phase 2 study testing an oral medication called oruvestat for treating non-proliferative diabetic retinopathy (NPDR), a leading cause of vision loss among people with diabetes. This study, known as SeeClear, aims to evaluate whether oruvestat can effectively halt or even improve the progression of this eye condition, which currently has no approved non-invasive treatment for its early stages. With approximately one in three individuals living with diabetes affected by NPDR, the potential impact of this research is significant for those looking to maintain their eyesight as they age.

The importance of this study cannot be understated. If successful, oruvestat could provide an early intervention option that is easy to administer, as it is taken orally rather than through injections or laser treatments typically reserved for later stages of the disease. This could mean better outcomes for many people with diabetes, as early treatment has the potential to preserve vision and improve overall quality of life. The study involves participants from 26 sites across the United States, Australia, and Southeast Asia, focusing on those with moderate-to-severe NPDR.

Currently, the research is in its early stages, with topline data expected in the fourth quarter of 2027. While the study has completed enrollment and participants are now undergoing treatment, it is important to note that oruvestat has not yet been proven effective in humans. As a clinical-stage therapy, it represents a promising avenue for future treatment but requires further validation through ongoing research.

For those interested in eye health and diabetes management, staying informed about developments like the SeeClear study could be beneficial, as new treatments may soon offer more options for preventing vision loss.

For more information, visit the original source at GlobeNewswire.